Literature DB >> 15591091

Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis.

Ronald A Lubet1, Konstantin Christov, Nomeli P Nunez, Steven D Hursting, Vernon E Steele, M Margaret Juliana, Isao Eto, Clinton J Grubbs.   

Abstract

Various aspects of the chemopreventive and chemotherapeutic properties of the RXR receptor agonist Targretin (LGD 1069) were examined in the methylnitrosourea (MNU)-induced model of mammary cancer. The administration of Targretin at dose levels of 60, 20 or 6.7 mg/kg body wt/day by gavage decreased the number of mammary tumors by 96, 85 and 78%, respectively. When Targretin was administered in the diet at 92 and 275 mg/kg diet cancer multiplicities were reduced by 78 and 92%, respectively. A wider range of dietary doses of Targretin at 15, 50 and 150 mg/kg diet reduced the number of mammary tumors by 38, 55 and 70%, respectively. Treatment of rats with different regimens of Targretin (250 mg/kg diet) yielded cancer multiplicities of 4.3 for non-treated rats, 0.5 for rats treated continuously with Targretin, 2.1 for rats treated with Targretin for 8 weeks followed by 10 weeks of the control diet and 1.6 for rats treated with Targretin alternating 3 days on and 4 days off. Targretin was also examined as a therapeutic agent by treating rats with at least one palpable mammary tumor for 5 weeks. A high dose of Targretin (272 mg/kg diet) caused partial or complete regression of approximately 65% of the cancers over this time period. In contrast, in animals treated with 15 mg Targretin/kg diet only 1 of 12 cancers showed significant regression. Finally, the effect of a limited exposure to Targretin (7 days) on cell proliferation and apoptosis in small mammary tumors was determined. Targretin at 150 mg/kg diet strongly decreased proliferation (75%) and increased apoptosis (300%), while a lower dose of Targretin (15 mg/kg diet, which still prevented 30% of cancers) had no effect on apoptosis but did decrease cell proliferation. Determination of serum IGF1 levels showed that treatment of rats with highly effective doses of Targretin at 272 mg/kg diet or at 60 or 20 mg/kg body wt/day by gavage caused significantly decreased serum IGF1 levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15591091     DOI: 10.1093/carcin/bgh338

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

1.  Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers.

Authors:  Ronald A Lubet; Brandy M Heckman-Stoddard; Jennifer T Fox; Fariba Moeinpour; M Margaret Juliana; Robert H Shoemaker; Clinton J Grubbs
Journal:  Cancer Prev Res (Phila)       Date:  2019-12-23

2.  The use of animal models for cancer chemoprevention drug development.

Authors:  Vernon E Steele; Ronald A Lubet
Journal:  Semin Oncol       Date:  2010-08       Impact factor: 4.929

Review 3.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

4.  DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents.

Authors:  Sebastiano La Maestra; Rosanna T Micale; Silvio De Flora; Francesco D'Agostini; Gancho Ganchev; Marietta Iltcheva; Nikolay Petkov; Vernon E Steele; Roumen Balansky
Journal:  Carcinogenesis       Date:  2012-10-05       Impact factor: 4.944

Review 5.  Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression.

Authors:  Ronald A Lubet; Vernon E Steele; Robert H Shoemaker; Clinton J Grubbs
Journal:  Cancer Prev Res (Phila)       Date:  2018-07-25

6.  Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.

Authors:  Leeann J Boerma; Gang Xia; Cheng Qui; Bryan D Cox; Michael J Chalmers; Craig D Smith; Susan Lobo-Ruppert; Patrick R Griffin; Donald D Muccio; Matthew B Renfrow
Journal:  J Biol Chem       Date:  2013-11-01       Impact factor: 5.157

7.  A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas.

Authors:  Stephan Woditschka; Jill D Haag; Ruth Sullivan; Michael N Gould
Journal:  Cancer Prev Res (Phila)       Date:  2009-02

8.  Quantitative receptor-based imaging of tumor proliferation with the sigma-2 ligand [(18)F]ISO-1.

Authors:  Kooresh I Shoghi; Jinbin Xu; Yi Su; June He; Douglas Rowland; Ying Yan; Joel R Garbow; Zhude Tu; Lynne A Jones; Ryuji Higashikubo; Kenneth T Wheeler; Ronald A Lubet; Robert H Mach; Ming You
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

9.  The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.

Authors:  Y Li; Y Zhang; J Hill; H-T Kim; Q Shen; R P Bissonnette; W W Lamph; P H Brown
Journal:  Br J Cancer       Date:  2008-03-25       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.